CRISPR biotech Intellia promotes R&D head to CEO post – FierceBiotech
FierceBiotech |
CRISPR biotech Intellia promotes R&D head to CEO post
FierceBiotech “After nearly four years of building Intellia and this exceptional team, the company is now poised to begin development of CRISPR/Cas9-based therapies,” explains Bermingham. “At this stage, Intellia requires a CEO with a track record of successful drug … Intellia Therapeutics Names John Leonard, MD, President and Chief Executive Officer Comparing Intellia Therapeutics (NTLA) & PDL BioPharma (PDLI) Intellia Therapeutics (NTLA) Lowered to D at TheStreet |
